Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: Depurative efficiency and clinical results in a long-term follow-up

Artificial Organs

Volumn 38, Issue 2, 2014, Pages 125-134

  Donati, Gabriele ^a   La Manna, Gaetano ^a   Cianciolo, Giuseppe ^a   Grandinetti, Valeria ^a   Carretta, Elisa ^b   Cappuccilli, Maria ^a   Panicali, Laura ^a   Iorio, Mario ^a   Piscaglia, Fabio ^a   Bolondi, Luigi ^a   Colì, Luigi ^a   Stefoni, Sergio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Detoxification; Hepatocyte growth factor; Liver failure; Molecular adsorbent recirculating system; Sequential Organ Failure Assessment; Survival

Indexed keywords

DIAGNOSIS; EFFICIENCY; PATIENT MONITORING; PATIENT REHABILITATION; PATIENT TREATMENT; REGRESSION ANALYSIS; RISK ASSESSMENT;

FAILURE ASSESSMENT; HEPATOCYTE GROWTH FACTOR; LIVER FAILURE; LIVER FUNCTIONS; MOLECULAR ADSORBENT RECIRCULATING SYSTEM; ORGAN FAILURE; ORTHOTOPIC LIVER TRANSPLANTATION; RECIRCULATING SYSTEM; SEQUENTIAL ORGAN FAILURE ASSESSMENT; SURVIVAL;

DETOXIFICATION;

ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; CHENODEOXYCHOLIC ACID; CHOLIC ACID; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN DIALYSIS; AMMONIA BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DETOXIFICATION; EXTRACORPOREAL DETOXIFICATION; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VERY ELDERLY; YOUNG ADULT;

DETOXIFICATION; HEPATOCYTE GROWTH FACTOR; LIVER FAILURE; MOLECULAR ADSORBENT RECIRCULATING SYSTEM; SEQUENTIAL ORGAN FAILURE ASSESSMENT; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; EXTRACORPOREAL CIRCULATION; FEMALE; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SORPTION DETOXIFICATION; TREATMENT OUTCOME; WAITING LISTS; YOUNG ADULT;

EID: 84894264220     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12106     Document Type: Article

References (53)

1. Martin JA, Smith BL, Mathews TJ, Ventura SJ. Births and deaths: preliminary data for 1998. National Vital Statistics Report Vol. 47, No. 25. Hyattsville, MD: National Center for Health Statistics, 1998.
2. Laleman W, Verbeke L, Meersseman P, etal. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol 2011;5:523-537.
3. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010;376:190-201.
4. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007;102:2459-2463.
5. Brandsaeter B, Höckerstedt K, Friman S, etal. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. Liver Transpl 2002;8:1055-1062.
6. Escorsell A, Mas A, de la Mata M. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007;13:1389-1395.
7. World Health Organization. Projections of mortality and burden of disease to 2030. Available at: http://www.who.int/healthinfo/statistics/bodprojections2030/en/index.html. Accessed December 20, 2012.
8. Matsushita M, Nosé Y. Artificial liver. Artif Organs 1986;10:378-384.
9. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289:217-222.
10. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Nöldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001;12(Suppl. 17):S75-82.
11. Stadlbauer V, Krisper P, Aigner R, etal. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006;10:R169.
12. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-1476.
13. Sen S, Davies NA, Mookerjee RP, etal. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004;10:1109-1119.
14. Novelli G, Rossi M, Ferretti G, etal. Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. Ther Apher Dial 2009;13:404-412.
15. Stefoni S, Colì L, Bolondi L, etal. Molecular adsorbent recirculating system (MARS) application in liver failure: clinical and hemodepurative results in 22 patients. Int J Artif Organs 2006;29:207-218.
16. Klammt S, Stange J, Mitzner SR, Peszynski P, Peters E, Liebe S. Extracorporeal liver support by recirculating albumin dialysis: analysing the effect of the first clinically used generation of the MARSystem. Liver 2002;22(Suppl. 2):30-34.
17. Schmidt LE, Sørensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001;7:1034-1039.
18. Heemann U, Treichel U, Loock J, etal. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36(4 Pt 1):949-958.
19. Laleman W, Wilmer A, Evenepoel P, etal. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10:R108.
20. Magosso E, Ursino M, Colì L, Baraldi O, Bolondi L, Stefoni S. A modeling study of bilirubin kinetics during Molecular Adsorbent Recirculating System sessions. Artif Organs 2006;30:285-300.
21. Gong D, Cruz D, Ronco C. Depurative capacity of molecular adsorbent recycling system (MARS): a focus on bilirubin removal. Int J Artif Organs 2008;3:875-881.
22. Klammt S, Brinkmann B, Mitzner S, etal. Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. Z Gastroenterol 2001;39(Suppl. 2):24-27.
23. Roda A, Kricka LJ, DeLuca M, Hofmann AF. Bioluminescence measurement of primary bile acids using immobilized 7 alpha-hydroxysteroid dehydrogenase: application to serum bile acids. J Lipid Res 1982;23:1354-1361.
24. Stadlbauer V, Krisper P, Beuers U, etal. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. ASAIO J 2007;53:187-193.
25. Abe T, Kobata H, Hanba Y, etal. Study of plasma exchange for liver failure: beneficial and harmful effects. Ther Apher Dial 2004;8:180-184.
26. Nakae H, Yonekawa C, Wada H, Asanuma Y, Sato T, Tanaka H. Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure. Ther Apher 2001;5:471-475.
27. Bektas M, Idilman R, Soyhan I, etal. Adjuvant therapeutic plasma exchange in liver failure. J Clin Gastroenterol 2008;45:517-521.
28. Krisper P, Stauber RE. Technology insight: artificial extracorporeal liver support-how does Prometheus compare with MARS? Nat Clin Pract Nephrol 2007;3:267-276.
29. Weiss JS, Gautam A, Lauff JJ, etal. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med 1983;309:147-150.
30. Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support-comparison of different methods. Ther Apher 2006;10:108-117.
31. Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif 2012;33:88-100.
32. Di Campli C, Zocco MA, Gaspari R, etal. The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc 2005;37:2551-2553.
33. Ilonen I, Koivusalo AM, Höckerstedt K, Isoniemi H. Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency. Transplant Proc 2006;38:3540-3543.
34. Ambrosino G, Naso A, Feltracco P, etal. Cytokines and liver failure: modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated with Molecular Adsorbent Recycling System (MARS). Acta Biomed 2003;74(Suppl. 2):7-9.
35. Isoniemi H, Koivusalo AM, Repo H, Ilonen I, Höckerstedt K. The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. Transplant Proc 2005;37:1088-1090.
36. Rocen M, Kieslichova E, Merta D, etal. The effect of Prometheus device on laboratory markers of inflammation and tissue regeneration in acute liver failure management. Transplant Proc 2010;42:3606-3611.
37. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 2001;26(Suppl. 1):188-202.
38. Rozga J. Hepatocyte proliferation in health and in liver failure. Med Sci Monit 2002;8:RA32-38.
39. Cianciolo G, La Manna G, Donati G, etal. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. Nephrol Dial Transplant 2011;26:646-652.
40. Stefoni S, Cianciolo G, Donati G, etal. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Nephron 2002;92:589-600.
41. Abramson S, Niles JL. Anticoagulation in continuous renal replacement therapy. Curr Opin Nephrol Hypertens 1999;8:701-707.
42. Cubattoli L, Teruzzi M, Cormio M, Lampati L, Pesenti A. Citrate anticoagulation during CVVH in high risk bleeding patients. Int J Artif Organs 2007;30:244-252.
43. Pozzato M. Citrate: an additional resource for anticoagulation in continuous replacement therapy. G Ital Nefrol 2012;29:20-26.
44. Kramer L, Bauer E, Joukhadar C, etal. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003;31:2450-2455.
45. Faybik P, Bacher A, Kozek-Langennecher SA, etal. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 2006;10:R24.
46. Meijers B, Laleman W, Vermeersch P, Nevens F, Wilmer A, Evenopoel P. A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System. Crit Care 2012;16:R20.
47. Mitzner SR, Stange J, Klammt S, etal. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-286.
48. Hessel FP, Mitzner SR, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Int 2003;23(Suppl. 3):66-72.
49. Kantola T, Koivusalo AM, Parmanen S, Höckerstedt K, Isoniemi H. Survival predictors in patients treated with a molecular adsorbent recirculating system. World J Gastroenterol 2009;15:3015-3024.
50. Bañares R, Nevens F, Larsen FS, etal. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013;57:1153-1162.
51. Oberkofler CE, Dutkowski P, Stocker R, etal. Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Crit Care 2010;14:R117.
52. Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001;34:255-261.
53. Yuan JZ, Ye QF, Zhao LL, etal. Preoperative risk factor analysis in orthotopic liver transplantation with pretransplant artificial liver support therapy. World J Gastroenterol 2006;12:5055-5059.